Their paper, published on August 22 in the journal Aging Cell, describes how mitochondrial dysfunction leads to accelerated aging as demonstrated by shortened telomeres, specialized DNA sequences that act as caps that stabilize the ends of chromosomes and are a key biomarker of premature aging.

"The shortening of telomeres is generally regarded as an important biomarker of aging, but for a long time, no one knew the mechanism. Now we are able to link mitochondrial dysfunction directly to the shortening of telomeres," said senior author Dr. Taosheng Huang, PhD, professor and chief of the division of genetics in the department of pediatrics in the University at Buffalo's Jacobs School of Medicine and Biomedical Sciences.

In a separate paper, published on July 25 in the journal Nature Communications, the researchers present a new technique they developed based on optogenetics that can help restore normal function to abnormal mitochondrial interactions, potentially reversing the cellular mechanisms that cause mitochondrial diseases and premature aging.

"In the Nature Communications paper, we describe a technology that we developed that allows us for the first time to directly manipulate the interactions between mitochondria and other organelles in the cell," Huang said. "By utilizing optogenetics to force a physical interaction between mitochondria and another cellular component, the lysosome, we were able to restore the mitochondria to a more normal size while also improving their energy production functions."

NIH team creates 3D structure of twinkle protein, sheds light on mitochondrial diseases
Researchers from the National Institutes of Health (NIH) have used cryo-electron microscopy and other techniques to create a 3D structure of the twinkle...

Link between genes, mitochondrial DNA reveals way to tackle cardiovascular disease
The discovery of a link between mitochondria, inflammation, and a pair of genes that help regulate blood cell growth has revealed a potential new target...

Astellas, Minovia partner on mitochondrial cell therapies
Astellas Pharma and Minovia Therapeutics have signed a strategic collaboration and license agreement for the research, development, and commercialization...